Maze Therapeutics (NASDAQ:MAZE) Raised to “Strong-Buy” at Truist Financial

Maze Therapeutics (NASDAQ:MAZE) was upgraded by investment analysts at Truist Financial to a “strong-buy” rating in a report issued on Tuesday,Zacks.com reports.

Several other equities analysts also recently issued reports on MAZE. Wall Street Zen downgraded shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 7th. Wells Fargo & Company started coverage on Maze Therapeutics in a research report on Thursday, December 4th. They set an “overweight” rating and a $55.00 target price on the stock. Mizuho raised Maze Therapeutics to a “strong-buy” rating in a report on Wednesday, March 11th. BTIG Research reissued a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a research report on Monday, March 9th. Finally, Wedbush raised their price target on Maze Therapeutics from $43.00 to $58.00 and gave the stock an “outperform” rating in a research note on Monday. Three equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $58.56.

Maze Therapeutics Price Performance

NASDAQ MAZE opened at $48.47 on Tuesday. The firm’s fifty day moving average price is $45.47 and its 200 day moving average price is $36.50. Maze Therapeutics has a 12 month low of $6.71 and a 12 month high of $53.65. The company has a market capitalization of $2.33 billion, a price-to-earnings ratio of -2.32 and a beta of 4.47.

Insider Transactions at Maze Therapeutics

In other news, SVP Amy Bachrodt sold 5,000 shares of the business’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $46.04, for a total transaction of $230,200.00. Following the transaction, the senior vice president directly owned 12,965 shares in the company, valued at $596,908.60. The trade was a 27.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CMO Harold Bernstein sold 30,000 shares of the stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $50.45, for a total transaction of $1,513,500.00. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 230,000 shares of company stock worth $9,768,292.

Institutional Investors Weigh In On Maze Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC increased its position in Maze Therapeutics by 318.0% during the 4th quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock worth $130,197,000 after purchasing an additional 2,390,713 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Maze Therapeutics by 218.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock valued at $34,615,000 after buying an additional 915,342 shares during the period. Marshall Wace LLP boosted its stake in shares of Maze Therapeutics by 3,868.5% in the third quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock valued at $20,166,000 after buying an additional 758,104 shares in the last quarter. Caligan Partners LP purchased a new stake in shares of Maze Therapeutics in the fourth quarter valued at approximately $22,794,000. Finally, ArrowMark Colorado Holdings LLC acquired a new position in Maze Therapeutics during the third quarter worth $14,135,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.